Portfolio, pipeline and payer footprint for the innovator companies shaping each therapy area — grouped by tier. Innovators only: no generics, CDMOs or CROs.
Swiss innovator with a deep rare-disease and immunology franchise. In AXLRx coverage, Novartis anchors the PNH complement story with iptacopan (Fabhalta), the first oral Factor B inhibitor to challenge the entrenched anti-C5 IV class.
Iptacopan oral pivot versus the anti-C5 IV class. Orphan-drug exclusion from IRA negotiation (US), NICE HST (UK) and SFDA lag (GCC).
PNH diagnosis pathway, FLAER flow-cytometry bottleneck and the treated-prevalent pool across US centres.
Why the orphan-drug exclusion shields anti-C5 agents from IRA negotiation, ICER's 2024 value verdict on iptacopan, and Part B vs Part D routing.
Anti-C5 IV therapy holds the GCC PNH market under NPHC/MOH specialist-centre gating, while iptacopan's 82.3% haemoglobin-response rate has not reached a single GCC formulary.
NPHC's KSA-first coverage model sets the de facto GCC access bar for anti-C5 agents — iptacopan faces a 12-24 month SFDA registration queue before NPHC even evaluates it.
Both ravulizumab and iptacopan cleared NICE's standard Technology Appraisal route (TA698 and TA1000) at the ordinary £20,000–£30,000/QALY bar — the real payer question is how fast NHS converts patients from IV ravulizumab to oral iptacopan, not which drug got the easier appraisal.
Iptacopan (Fabhalta) reached French PNH patients through AP1 — HAS granted accès précoce authorisation two weeks before the drug's EU marketing authorisation even took effect. Any new PNH entrant must be dossier-ready for this track before, not after, EU approval.
Iptacopan's substantial-benefit finding gave Germany real negotiating leverage over Novartis. Six months on, no negotiated net price has surfaced in the Lauer-Taxe — the pricing signal this model is built to catch before a launch-sequencing decision locks in the wrong assumption.
NICE has cleared every modern PNH anti-complement therapy, from ravulizumab to crovalimab, through the standard £20,000-30,000 Technology Appraisal route rather than the more generous Highly Specialised Technologies threshold, each via a confidential patient access scheme.
Binding constraint: beat iptacopan's oral bar in the EVH-anaemia cohort anti-C5 can't resolve — inside a pricing ceiling iptacopan already set.
15,000-20,000 Americans carry a PNH clone, but only about 3,500 reach complement-inhibitor therapy, and up to 1,200 of them stay anemic on it. This model sizes every gap in between.
~600-750 UK PNH patients are on active complement-inhibitor therapy against a reconciled total prevalence near 1,500; the other 750-900 are monitored-only or undiagnosed, and this model sizes the gap.
France's PMSI hospital database counts 897 PNH patients over five years; Orphanet's older estimate puts national prevalence at 850-1,000. Only 270 of them, per the manufacturer's own estimate, are eligible for a second-line oral agent.
Seven institutions across Riyadh, Jeddah, Dubai, and Abu Dhabi concentrate the GCC's confirmed PNH caseload, and just 5 to 8 physicians function as genuine adoption gatekeepers. That kind of concentration is exactly what this workbook sizes before any individual name enters it.
Five NHS Highly Specialised Services centres, anchored by the Leeds National PNH Service, concentrate fewer than 25 consultants managing over 90% of the UK's PNH caseload. That kind of institutional concentration is exactly the signal this workbook sizes before any individual name enters it.
Saint-Louis Hospital anchors France's MaRIH-coordinated PNH reference network of 14 competence centres, but only 24 of the 50-plus centres in the national clone-observatory network actively report into it. That kind of institutional structure is exactly what this workbook sizes before any individual name enters it.
First-mover oral complement inhibition in GCC PNH is a closing window: SFDA registration ahead of iptacopan, not competitive differentiation from entrenched anti-C5, decides commercial success.
All three UK PNH agents have cleared NICE via the standard Technology Appraisal route: ravulizumab (TA698), iptacopan (TA1000), and crovalimab. Convenience and switch dynamics, not pathway-driven affordability, now determine NHS share.
Iptacopan's ~$550,000 annual WAC sits roughly 71% above ICER's own $156,000-157,000 value-based benchmark, yet the orphan-drug exclusion keeps anti-C5 incumbents priced outside IRA's reach entirely, the two forces any new US PNH entrant must price against.
The Leeds National PNH Registry tracks about 600 UK patients on complement-inhibitor therapy, but AXLRx's own Launch Readiness research cites a broader estimate near 1,500 total patients and 1,000 treated. Reconciling which count anchors a sizing model is the open question.
Germany's DGHO Onkopedia guideline states plainly that Germany-specific PNH prevalence and incidence figures do not exist. It borrows 16 cases and 1.3 new diagnoses per million annually from British and French registries, and routes all case-finding through just two national centres, Ulm and Essen.
An estimated 2,000-3,000 Gulf patients carry a clinically significant PNH clone, but only about 400 are confirmed in national registries, and just 150-250 reach complement-inhibitor therapy. Diagnostic capacity, not drug access, is the constraint this model sizes.
Germany has no domestic PNH prevalence count of its own; DGHO's Onkopedia guideline borrows a 16-per-million estimate from British and French registries. Only two national centres, Ulm and Essen, anchor referral.
The EVH-dominant population Ultomiris cannot resolve, the standard NICE Technology Appraisal bar every PNH agent has now cleared, and the PAS discount required to hit it before MHRA approval.
NICE has cleared four modern PNH anti-complement therapies (ravulizumab TA698, pegcetacoplan TA778, iptacopan TA1000 and crovalimab TA1019) through its standard £20,000-30,000 Technology Appraisal route, each contingent on a confidential commercial arrangement, never the Highly Specialised Technologies threshold. A new submission inherits an unbroken standard-STA precedent it must be built to clear from the first dossier decision.
PNH diagnostic pathway, FLAER flow-cytometry bottleneck and the undiagnosed clonal pool across GCC specialist centres.
Germany has no confirmed PNH prevalence data of its own. The DGHO's Onkopedia guideline borrows an estimate from British and French registries, and diagnosis funnels through just two national referral centres.
Iptacopan's orphan-drug status let it clear Germany's AMNOG process with an established additional benefit and no comparator dossier at all. Ravulizumab's only PNH-specific G-BA review found no added benefit.
HAS splits PNH into two tracks: ravulizumab holds SMR important and first-line, priced at €14,988.66 per 1100mg vial. Iptacopan cleared only ASMR III, restricted to second-line, its €29,590.96 box price negotiated against a manufacturer-declared population of 270 patients.
US PNH prevalence spans 15,000 to 20,000 patients across three phenotypes, but only about 3,500 are on complement-inhibitor therapy. A 2.4-year average diagnostic delay, plus 200 to 400 patients a year undertreated at non-PNH centres, accounts for most of that gap.
France's own national hospitalization database puts PNH prevalence near 1 in 94,000, 897 patients from 2018 to 2022, lower than the 16-per-million figure Germany's DGHO Onkopedia guideline borrows from French and UK registries.
France's PMSI national hospitalization database identified 897 PNH patients between 2018 and 2022, putting 2022 prevalence near 1 in 94,000, below the 1-in-70,000-to-80,000 range Orphanet and France's national rare disease plan have long cited.
Iptacopan's orphan-drug status let it clear AMNOG with an established additional benefit and a substantial quality-of-life finding. Ravulizumab, tested on Germany's only PNH-specific G-BA review to date, found no added benefit at all.
Iptacopan already cleared Germany's AMNOG process with a substantial benefit finding and no comparator dossier. A new entrant without orphan-pathway standing has to win that same finding the hard way, through IQWiG.
Saudi Arabia's rare disease registry counts about 400 confirmed PNH cases. Global prevalence rates, adjusted for the region's 25-50% consanguinity rate, imply a true GCC PNH population 20-30% higher, and fewer than 15 labs across six countries can even run the diagnostic test.
Leeds National Registry data, FLAER access without referral, and the 30% PNH-aplasia overlap defining the NHS commercial picture.
GCC anti-C5 tender pricing already runs 40-60% of US WAC, anchored to whichever EU comparator prices lowest, then compounded with a further 10-20% negotiation discount. Iptacopan has to clear the same cascade, still 12-24 months from SFDA registration.
HAS rated iptacopan ASMR III but restricted it to second-line use, while ravulizumab holds SMR important and first-line status. CEPS negotiated iptacopan's price against a manufacturer-estimated population of just 270 patients.
HAS restricted iptacopan to second-line use only, anemic patients with haemoglobin below 10 g/dL after at least six months on an anti-C5 inhibitor, and rated it ASMR III. Ravulizumab holds the first-line position with SMR important.